抗真菌治療の世界市場

抗真菌治療の世界市場は2030年までに191億米ドルに達する見込み

2024年に164億米ドルと推定される抗真菌治療の世界市場は、分析期間2024-2030年にCAGR 2.6%で成長し、2030年には191億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアゾール薬剤クラス別は、CAGR 4.2%を記録し、分析期間終了時には54億米ドルに達すると予測されます。エキノカンディン類薬剤クラス別セグメントの成長率は、分析期間中CAGR 1.6%と推定されます。

米国市場は45億米ドルと推定、中国はCAGR 5.3%で成長予測

米国の抗真菌治療市場は2024年に45億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに38億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と2.0%と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の抗真菌治療市場- 主要動向と促進要因のまとめ

抗真菌治療の需要が世界的に高まっている理由とは？

抗真菌治療の世界の需要は一貫して増加傾向にあり、特に高齢者、免疫不全患者、慢性疾患患者などの脆弱な人々の間で真菌感染症が急増しています。カンジダ症、水虫、白癬、爪真菌症などの病態は、公共のジム、共同シャワー、窮屈な靴の普及といった生活習慣の要因によって、ますます一般的になっています。また、世界の旅行や都市化の急速な拡大により、真菌病原体が新たな地域に持ち込まれ、以前は感染していなかった地域での感染率が増加しています。さらに、院内真菌感染症は、特にICU患者や臓器移植、化学療法、長期の抗生物質治療を受けている患者の間で深刻な問題となっています。これらの感染症は早期発見が難しいだけでなく、放置すれば生命を脅かすこともあります。世界各地の気候変動と湿度の上昇は、真菌の増殖に理想的な条件を作り出し、感染症の蔓延をさらに助長しています。啓蒙キャンペーンや診断方法の改善により、発見率が向上し、治療を受ける人が増えています。一方、かつて真菌感染症（特に皮膚、頭皮、爪に感染するもの）につきまとっていたスティグマ（烙印）は薄れつつあり、より早期の治療介入と、一般用医薬品（OTC）や処方箋による抗真菌薬に対する消費者の開放が促されています。また、オンライン薬局やe-ヘルスプラットフォームの利便性も抗真菌治療へのアクセスを向上させ、より幅広い利用を促し、先進国・発展途上国を問わず世界の需要の拡大に貢献しています。

ドラッグデリバリーの革新は治療効果をどのように高めているか？

製薬技術における最近の技術革新は、薬剤をより効果的で的を絞った、患者に優しいものにすることで、抗真菌薬業界を再構築しています。従来の抗真菌療法は、治療期間の長期化、吸収の悪さ、毒性の高さ、耐性菌の発生といった制限に悩まされることが多くなりました。今日、リポソーム型アムホテリシンB、トリアゾール系抗真菌薬、エキノカンジン系抗真菌薬などの先進的な製剤は、より広範囲な活性、より優れた忍容性、より少ない副作用を提供しています。これらの新しい薬剤は、かつては治療の選択肢が限られていた侵襲性真菌感染症や耐性真菌感染症を治療することができます。ナノテクノロジーの台頭により、ナノ製剤や脂質ベースのデリバリーシステムが開発され、特に全身性の真菌症において、薬剤のバイオアベイラビリティを高め、感染部位への標的送達が可能となりました。局所抗真菌治療もまた、吸収の速いゲル、スプレー、ラッカーによって改善され、全身への曝露を最小限に抑えながら局所的な治療を行うことができるようになりました。経口薬や点滴薬も、小児や老年患者を含む特定の患者群に合わせ、用量を調節したり徐放化したりできるようになりました。さらに、抗真菌剤と抗炎症剤の併用療法は、皮膚真菌症に対して、より迅速な治療と再発率の減少を目的として人気を集めています。製薬業界はまた、不適切な使用を減らし、耐性パターンを監視し、エビデンスに基づいた処方を推進するために、抗真菌スチュワードシップ・プログラムに注力しています。これらの技術革新は治療の選択肢を広げ、服薬アドヒアランスを向上させることで、転帰をより良いものにし、患者やヘルスケアプロバイダーの信頼を高めています。これらの技術革新が相まって、抗真菌治療はより正確で効率的、そして利用しやすい医療へと変貌を遂げつつあります。

ヘルスケア・インフラと消費者行動は市場拡大においてどのような役割を果たすのか？

抗真菌治療市場の拡大には、ヘルスケアインフラと進化する消費者行動が極めて重要な役割を果たしています。高所得国では、診断ラボ、専門治療ユニット、高度な医薬品が広く普及しているため、真菌感染症のタイムリーな特定と効果的な管理が可能です。病院、皮膚科クリニック、プライマリケアセンターは、表在性・全身性感染症の両方に対応するための設備が整っており、電子カルテや電子処方により、より良いモニタリングとフォローアップが容易になっています。一方、新興諸国ではヘルスケアの改善への投資が進んでおり、抗真菌治療がより身近なものとなり、公衆衛生活動も改善されています。パンデミック後は遠隔医療サービスが急増し、遠隔地や十分な医療サービスを受けられない地域の患者でも、真菌症に対する診察や処方をタイムリーに受けられるようになり、疾病負担が軽減されています。同時に、消費者の行動も積極的な健康管理へと進化しています。より多くの人々が予防医療に取り組み、日常的に皮膚や爪、頭皮に感染の兆候がないか検査し、症状が悪化する前に初期治療を行うようになっています。薬局、スーパーマーケット、オンラインストアなど、化粧品や健康食品の小売チャネルで抗真菌製品が入手できるようになったことは、このシフトに対応するためであり、控えめで手頃な価格の選択肢を提供するものです。また、天然成分やオーガニック処方に対する消費者の嗜好も、ティーツリーオイル、ニーム、クローブエキスを配合した抗真菌クリーム、パウダー、シャンプーの需要を押し上げています。さらに、世界の健康危機による衛生意識の高まりが、抗真菌石鹸や除菌製品の使用を促しています。健康リテラシーが向上し、文化的な偏見が薄れるにつれて、より多くの消費者が真菌感染症の治療と予防を優先するようになり、地域や人口統計を問わず市場の成長がさらに加速するものと思われます。

抗真菌治療薬の世界的成長を促進する主な要因は何か？

抗真菌治療市場の成長は、疫学的、技術的、行動的、規制的要因が組み合わさって、世界のヘルスケアエコシステム全体における需要と供給を形成していることが原動力となっています。主要な促進要因は、真菌感染症の有病率の上昇であり、高齢化、糖尿病や免疫抑制性疾患の増加、侵襲的な外科手術の急増により、その感受性が高まっています。もう一つの重要な要因は、免疫抑制剤や化学療法の使用拡大であり、これらは身体の自然な防御機能を低下させ、日和見真菌感染症に対する脆弱性を高める。既存の抗真菌薬に対する治療抵抗性も、より強力な新しい治療法の開発と採用を促しています。真菌バイオマーカーや迅速PCR検査などの創薬や診断の進歩により、早期かつ正確な発見が容易になり、タイムリーな治療開始が可能となっています。さらに、製薬業界が抗真菌薬の研究開発に注力することで、より安全性が高く、適応症も拡大したパイプラインが生まれつつあります。オーファンドラッグ（希少疾病用医薬品）の認定や迅速承認といった規制上のインセンティブは、特に希少な薬剤耐性真菌病原体に対する技術革新をさらに促進しています。多くの地域で健康保険が適用され、保険償還政策が実施されているため、抗真菌療法はより多くの人々にとって利用しやすいものとなっています。オンライン薬局のプラットフォームや消費者への直接販売が急増したことで、アクセスに対する従来の障壁が取り除かれ、セルフケアや早期介入が奨励されるようになりました。さらに、メディア、公衆衛生キャンペーン、皮膚科のインフルエンサーによる一般市民の認知度の向上は、偏見をなくし、適時に治療を受ける動機付けとなっています。これらの要因が相まって、抗真菌治療市場は力強い成長軌道を描いており、急性期医療環境と消費者向け医療の両領域で確実に拡大しています。

セグメント

薬剤クラス（アゾール系薬剤クラス、エキノカンディン系薬剤クラス、ポリエン系薬剤クラス、アリルアミン系薬剤クラス、ピリミジン系薬剤クラス、その他薬剤クラス）、投与経路（経口投与経路、局所投与経路、非経口投与経路）、適応（皮膚糸状菌症適応、アスペルギルス症適応、カンジダ症適応、侵襲性カンジダ症適応、外陰膣カンジダ症適応、口腔/咽頭/食道カンジダ症適応、その他の適応）、病原体（カンジダ病原体、アスペルギルス病原体、クリプトコッカス病原体、コクシジオイデス菌病原体、接合菌病原体、白癬菌病原体、その他の病原体）;エンドユーザー（病院＆クリニックエンドユーザー、皮膚科クリニックエンドユーザー、その他のエンドユーザー）

調査対象企業の例（注目の32社）

• Astellas Pharma Inc.
• Bayer AG
• Biocon Limited
• Cipla Limited
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Glenmark Pharmaceuticals
• GSK（GlaxoSmithKline）
• Hetero Drugs Limited
• LEO Pharma A/S
• Lupin Limited
• Mylan N.V.（now part of Viatris）
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sandoz（a Novartis division）
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Zydus Cadila

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antifungal Treatment Market to Reach US$19.1 Billion by 2030

The global market for Antifungal Treatment estimated at US$16.4 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Echinocandins Drug Class segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 5.3% CAGR

The Antifungal Treatment market in the U.S. is estimated at US$4.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Antifungal Treatment Market - Key Trends & Drivers Summarized

Why Is Demand for Antifungal Treatment Escalating Across the Globe?

The global demand for antifungal treatment is witnessing a consistent upward trend, driven by a sharp increase in fungal infections, particularly among vulnerable populations such as the elderly, immunocompromised patients, and individuals with chronic illnesses. Conditions such as candidiasis, athlete’s foot, ringworm, and onychomycosis are increasingly common, fueled by lifestyle factors like the widespread use of public gyms, communal showers, and tight footwear. The rapid expansion of global travel and urbanization has also introduced fungal pathogens into new regions, increasing infection rates in previously unaffected areas. Moreover, hospital-acquired fungal infections have become a serious concern, particularly among ICU patients and those undergoing organ transplants, chemotherapy, or long-term antibiotic treatment. These infections are not only hard to detect early but can also be life-threatening if left untreated. Climate change and higher humidity levels in many parts of the world have created ideal conditions for fungal growth, contributing further to the prevalence of infections. Public awareness campaigns and improved diagnostic methods are increasing detection rates, leading more individuals to seek treatment. Meanwhile, the stigma that once surrounded fungal infections-particularly those affecting the skin, scalp, and nails-is diminishing, prompting earlier intervention and greater consumer openness to over-the-counter (OTC) and prescription antifungal medications. The convenience of online pharmacies and e-health platforms has also enhanced access to antifungal treatments, encouraging wider use and contributing to the growing global demand across both developed and developing regions.

How Are Innovations in Drug Formulation and Delivery Enhancing Treatment Effectiveness?

Recent innovations in pharmaceutical technology are reshaping the antifungal treatment landscape by making medications more effective, targeted, and patient-friendly. Traditional antifungal therapies often suffered from limitations such as prolonged treatment durations, poor absorption, high toxicity, and resistance development. Today, advanced drug formulations-including liposomal amphotericin B, triazoles, and echinocandins-are offering broader-spectrum activity, better tolerability, and fewer side effects. These newer agents can treat invasive and resistant fungal infections that once had limited therapeutic options. The rise of nanotechnology has enabled the development of nanoformulations and lipid-based delivery systems that enhance drug bioavailability and target delivery to infection sites, especially in systemic mycoses. Topical antifungal treatments have also improved with fast-absorbing gels, sprays, and lacquers that provide localized treatment while minimizing systemic exposure. Oral and intravenous medications are now being tailored for specific populations, including pediatric and geriatric patients, with adjusted dosages and extended-release versions. Furthermore, combination therapies that include antifungal and anti-inflammatory agents are gaining popularity for skin-based fungal conditions to provide faster relief and reduce recurrence rates. The pharmaceutical industry is also focusing on antifungal stewardship programs to reduce inappropriate use, monitor resistance patterns, and promote evidence-based prescribing. These innovations are expanding treatment options and improving adherence, leading to more successful outcomes and increasing trust among patients and healthcare providers alike. Collectively, they are transforming antifungal treatment into a more precise, efficient, and accessible field of medicine.

What Role Do Healthcare Infrastructure and Consumer Behavior Play in Market Expansion?

Healthcare infrastructure and evolving consumer behavior are playing pivotal roles in the expansion of the antifungal treatment market. In high-income countries, the widespread availability of diagnostic labs, specialized care units, and advanced pharmaceuticals ensures timely identification and effective management of fungal infections. Hospitals, dermatology clinics, and primary care centers are better equipped to handle both superficial and systemic infections, while electronic medical records and e-prescribing facilitate better monitoring and follow-up. In contrast, developing countries are increasingly investing in healthcare upgrades, resulting in more accessible antifungal treatments and improved public health outreach. Telemedicine services have surged post-pandemic, allowing patients in remote or underserved areas to receive timely consultations and prescriptions for fungal conditions, thus reducing disease burden. Simultaneously, consumer behavior is evolving toward proactive health management. More people are engaging in preventive care, routinely inspecting skin, nails, and scalp for signs of infection, and treating early symptoms before they escalate. The availability of antifungal products in cosmetic and wellness retail channels-such as pharmacies, supermarkets, and online stores-caters to this shift, offering discreet, affordable options. Consumer preference for natural and organic formulations has also driven demand for antifungal creams, powders, and shampoos featuring tea tree oil, neem, and clove extracts. Moreover, rising hygiene awareness due to global health crises has prompted greater use of antifungal soaps and sanitizing products. As health literacy improves and cultural stigmas fade, more consumers are likely to prioritize treatment and prevention of fungal infections, further accelerating the market's growth across regions and demographics.

What Are the Primary Drivers Fueling the Global Growth of Antifungal Treatments?

The growth in the antifungal treatment market is driven by a combination of epidemiological, technological, behavioral, and regulatory factors that are shaping demand and supply across global healthcare ecosystems. A key driver is the rising prevalence of fungal infections, fueled by aging populations, increasing rates of diabetes and immunosuppressive diseases, and a surge in invasive surgical procedures that heighten susceptibility. Another significant factor is the expanding use of immunosuppressive drugs and chemotherapy, which compromise the body's natural defenses and increase vulnerability to opportunistic fungal infections. Resistance to existing antifungal drugs is also encouraging the development and adoption of newer, more potent treatments. Advances in drug discovery and diagnostics-such as fungal biomarkers and rapid PCR tests-are facilitating early and accurate detection, prompting timely treatment initiation. Moreover, the pharmaceutical industry’s focus on antifungal R&D is yielding pipeline drugs with better safety profiles and expanded indications. Regulatory incentives such as orphan drug status and fast-track approvals are further stimulating innovation, especially for rare and drug-resistant fungal pathogens. Health insurance coverage and reimbursement policies in many regions now include antifungal therapies, making them more accessible to a broader population. The surge in online pharmacy platforms and direct-to-consumer marketing has removed traditional barriers to access, encouraging self-care and early intervention. Additionally, greater public awareness, driven by media, public health campaigns, and dermatology influencers, is reducing stigma and motivating individuals to seek timely care. Together, these drivers are forging a robust growth trajectory for the antifungal treatment market, ensuring its expansion across both acute care settings and consumer health domains.

SCOPE OF STUDY:

The report analyzes the Antifungal Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class, Other Drug Classes); Administration Route (Oral Route of Administration, Topical Route of Administration, Parenteral Route of Administration); Indication (Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication, Other Indications); Pathogen (Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen, Other Pathogens); End-Use (Hospitals & Clinics End-Use, Dermatology Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Astellas Pharma Inc.
• Bayer AG
• Biocon Limited
• Cipla Limited
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Glenmark Pharmaceuticals
• GSK (GlaxoSmithKline)
• Hetero Drugs Limited
• LEO Pharma A/S
• Lupin Limited
• Mylan N.V. (now part of Viatris)
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sandoz (a Novartis division)
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Antifungal Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Fungal Infections Throws the Spotlight on Antifungal Therapeutics
  • Growth in Immunocompromised Populations and ICU Admissions Drives Prescription Demand
  • OEMs Developing Broad-Spectrum and Targeted Antifungals Improve Treatment Outcomes
  • Use of Azoles, Echinocandins, and Polyenes Across Diverse Indications Supports Therapeutic Breadth
  • Expansion of Topical, Oral, and IV Formulations Enhances Delivery Flexibility
  • OEM Innovation in Liposomal and Nanoparticle-Based Delivery Improves Bioavailability
  • Rising Antifungal Resistance Trends Accelerate Development of Novel MOA-Based Drugs
  • Use in Dermatology, Oncology, and Transplant Medicine Broadens Institutional Usage
  • Integration With Diagnostic and Susceptibility Testing Enhances Precision Prescribing
  • OEMs Targeting Fungal Biofilms and Recurrent Infections Address Unmet Clinical Needs
  • Growth in OTC Antifungal Creams and Powders Supports Self-Care Market
  • Increased Veterinary Use in Companion and Farm Animals Adds Non-Human Revenue Streams
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antifungal Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antifungal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Polyenes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Polyenes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Polyenes Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Allylamine Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Allylamine Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Allylamine Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pyrimidines Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pyrimidines Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Pyrimidines Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Dermatophytosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Dermatophytosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Dermatophytosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Aspergillosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Aspergillosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Aspergillosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Candidiasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Invasive Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Invasive Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Invasive Candidiasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Vulvovaginal Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Vulvovaginal Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Vulvovaginal Candidiasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Mouth / Throat / Esophageal Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Mouth / Throat / Esophageal Candidiasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Mouth / Throat / Esophageal Candidiasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Candida Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Candida Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Candida Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Aspergillus Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Aspergillus Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Aspergillus Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Cryptococcus Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Cryptococcus Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Cryptococcus Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Coccidioides Immitis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Coccidioides Immitis Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Coccidioides Immitis Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Zygomycetes Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Zygomycetes Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: World 16-Year Perspective for Zygomycetes Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Trichophyton Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Trichophyton Pathogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: World 16-Year Perspective for Trichophyton Pathogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Other Pathogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: World 16-Year Perspective for Other Pathogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 65: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 68: World Recent Past, Current & Future Analysis for Dermatology Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: World Historic Review for Dermatology Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: World 16-Year Perspective for Dermatology Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 71: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 74: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: World Historic Review for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: World 16-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 77: World Recent Past, Current & Future Analysis for Topical Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: World Historic Review for Topical Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: World 16-Year Perspective for Topical Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 80: World Recent Past, Current & Future Analysis for Parenteral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: World Historic Review for Parenteral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: World 16-Year Perspective for Parenteral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 83: USA Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: USA Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: USA 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 86: USA Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: USA Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: USA 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 89: USA Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: USA Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: USA 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 92: USA Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: USA Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: USA 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 95: USA Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: USA Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: USA 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 98: Canada Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Canada Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Canada 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 101: Canada Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Canada Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Canada 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 104: Canada Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Canada Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Canada 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 107: Canada Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Canada Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Canada 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 110: Canada Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Canada Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Canada 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• JAPAN
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 113: Japan Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Japan Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Japan 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 116: Japan Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Japan Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Japan 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 119: Japan Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Japan Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Japan 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 122: Japan Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Japan Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Japan 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 125: Japan Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Japan Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Japan 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• CHINA
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 128: China Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: China Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: China 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 131: China Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: China Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: China 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 134: China Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: China Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: China 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 137: China Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: China Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: China 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 140: China Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: China Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: China 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• EUROPE
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 143: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Europe Historic Review for Antifungal Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Europe 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 146: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Europe Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Europe 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 149: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Europe Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Europe 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 152: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Europe Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Europe 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 155: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Europe Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Europe 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 158: Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Europe Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Europe 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• FRANCE
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 161: France Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: France Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: France 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 164: France Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: France Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: France 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 167: France Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: France Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: France 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 170: France Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: France Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: France 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 173: France Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: France Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: France 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• GERMANY
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 176: Germany Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Germany Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Germany 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 179: Germany Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Germany Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Germany 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 182: Germany Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Germany Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Germany 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 185: Germany Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Germany Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Germany 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 188: Germany Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Germany Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Germany 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 191: Italy Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Italy Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Italy 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 194: Italy Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Italy Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Italy 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 197: Italy Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Italy Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Italy 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 200: Italy Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Italy Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Italy 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 203: Italy Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Italy Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Italy 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 206: UK Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UK Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: UK 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 209: UK Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: UK Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: UK 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 212: UK Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: UK Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: UK 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 215: UK Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: UK Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: UK 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 218: UK Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: UK Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: UK 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 221: Spain Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Spain Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Spain 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 224: Spain Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Spain Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Spain 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 227: Spain Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Spain Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Spain 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 230: Spain Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Spain Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Spain 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 233: Spain Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Spain Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Spain 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 236: Russia Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Russia Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Russia 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 239: Russia Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Russia Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Russia 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 242: Russia Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Russia Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Russia 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 245: Russia Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Russia Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Russia 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 248: Russia Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Russia Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Russia 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 251: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Europe Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Europe 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Europe Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Europe 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Europe Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Europe 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Europe Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Europe 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 263: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Europe Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Europe 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Asia-Pacific Historic Review for Antifungal Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Asia-Pacific 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 269: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Asia-Pacific Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Asia-Pacific 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 272: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Asia-Pacific Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Asia-Pacific 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 275: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Asia-Pacific Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Asia-Pacific 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 278: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Asia-Pacific Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Asia-Pacific 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 281: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Asia-Pacific Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Asia-Pacific 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 284: Australia Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Australia Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Australia 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 287: Australia Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Australia Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Australia 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 290: Australia Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Australia Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Australia 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 293: Australia Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Australia Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Australia 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 296: Australia Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Australia Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Australia 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• INDIA
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 299: India Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: India Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: India 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 302: India Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: India Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: India 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 305: India Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: India Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: India 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 308: India Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: India Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: India 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 311: India Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: India Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: India 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 314: South Korea Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: South Korea Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: South Korea 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 317: South Korea Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: South Korea Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: South Korea 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 320: South Korea Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: South Korea Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: South Korea 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 323: South Korea Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: South Korea Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: South Korea 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 326: South Korea Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: South Korea Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: South Korea 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 329: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Asia-Pacific Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Rest of Asia-Pacific 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 332: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Asia-Pacific Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Rest of Asia-Pacific 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 335: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Rest of Asia-Pacific Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Rest of Asia-Pacific 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 338: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Rest of Asia-Pacific Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Rest of Asia-Pacific 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 341: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Rest of Asia-Pacific Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Rest of Asia-Pacific 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 344: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 345: Latin America Historic Review for Antifungal Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Latin America 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 347: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Latin America Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Latin America 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 350: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Latin America Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Latin America 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 353: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Latin America Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Latin America 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 356: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Latin America Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Latin America 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 359: Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Latin America Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Latin America 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 362: Argentina Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Argentina Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Argentina 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 365: Argentina Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Argentina Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Argentina 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 368: Argentina Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Argentina Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Argentina 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 371: Argentina Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Argentina Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Argentina 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 374: Argentina Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Argentina Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Argentina 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 377: Brazil Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Brazil Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Brazil 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 380: Brazil Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Brazil Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Brazil 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 383: Brazil Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Brazil Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Brazil 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 386: Brazil Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Brazil Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Brazil 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 389: Brazil Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Brazil Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Brazil 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 392: Mexico Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Mexico Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Mexico 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 395: Mexico Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Mexico Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Mexico 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 398: Mexico Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Mexico Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Mexico 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 401: Mexico Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Mexico Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Mexico 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 404: Mexico Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Mexico Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Mexico 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 407: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Latin America Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Rest of Latin America 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 410: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Rest of Latin America Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Rest of Latin America 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 413: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Rest of Latin America Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 415: Rest of Latin America 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 416: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Rest of Latin America Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 418: Rest of Latin America 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 419: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Rest of Latin America Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 421: Rest of Latin America 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 422: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 423: Middle East Historic Review for Antifungal Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 424: Middle East 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 425: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Middle East Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 427: Middle East 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 428: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Middle East Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 430: Middle East 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 431: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Middle East Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 433: Middle East 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 434: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Middle East Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 436: Middle East 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 437: Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Middle East Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 439: Middle East 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 440: Iran Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Iran Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 442: Iran 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 443: Iran Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Iran Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 445: Iran 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 446: Iran Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Iran Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 448: Iran 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 449: Iran Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Iran Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 451: Iran 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 452: Iran Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Iran Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 454: Iran 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 455: Israel Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Israel Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 457: Israel 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 458: Israel Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Israel Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 460: Israel 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 461: Israel Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: Israel Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 463: Israel 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 464: Israel Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: Israel Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 466: Israel 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 467: Israel Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Israel Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 469: Israel 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 470: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: Saudi Arabia Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 472: Saudi Arabia 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 473: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: Saudi Arabia Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 475: Saudi Arabia 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 476: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Saudi Arabia Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 478: Saudi Arabia 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 479: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Saudi Arabia Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 481: Saudi Arabia 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 482: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Saudi Arabia Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 484: Saudi Arabia 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 485: UAE Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: UAE Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 487: UAE 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 488: UAE Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: UAE Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 490: UAE 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 491: UAE Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: UAE Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 493: UAE 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 494: UAE Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: UAE Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 496: UAE 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 497: UAE Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 498: UAE Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 499: UAE 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 500: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Rest of Middle East Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 502: Rest of Middle East 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 503: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Rest of Middle East Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 505: Rest of Middle East 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 506: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 507: Rest of Middle East Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 508: Rest of Middle East 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 509: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 510: Rest of Middle East Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 511: Rest of Middle East 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 512: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 513: Rest of Middle East Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 514: Rest of Middle East 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030
• AFRICA
  • Antifungal Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 515: Africa Recent Past, Current & Future Analysis for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 516: Africa Historic Review for Antifungal Treatment by Drug Class - Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 517: Africa 16-Year Perspective for Antifungal Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Echinocandins Drug Class, Polyenes Drug Class, Allylamine Drug Class, Pyrimidines Drug Class and Other Drug Classes for the Years 2014, 2025 & 2030
  • TABLE 518: Africa Recent Past, Current & Future Analysis for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 519: Africa Historic Review for Antifungal Treatment by Indication - Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 520: Africa 16-Year Perspective for Antifungal Treatment by Indication - Percentage Breakdown of Value Sales for Dermatophytosis Indication, Aspergillosis Indication, Candidiasis Indication, Invasive Candidiasis Indication, Vulvovaginal Candidiasis Indication, Mouth / Throat / Esophageal Candidiasis Indication and Other Indications for the Years 2014, 2025 & 2030
  • TABLE 521: Africa Recent Past, Current & Future Analysis for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 522: Africa Historic Review for Antifungal Treatment by Pathogen - Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 523: Africa 16-Year Perspective for Antifungal Treatment by Pathogen - Percentage Breakdown of Value Sales for Candida Pathogen, Aspergillus Pathogen, Cryptococcus Pathogen, Coccidioides Immitis Pathogen, Zygomycetes Pathogen, Trichophyton Pathogen and Other Pathogens for the Years 2014, 2025 & 2030
  • TABLE 524: Africa Recent Past, Current & Future Analysis for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 525: Africa Historic Review for Antifungal Treatment by End-Use - Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 526: Africa 16-Year Perspective for Antifungal Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Dermatology Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • TABLE 527: Africa Recent Past, Current & Future Analysis for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 528: Africa Historic Review for Antifungal Treatment by Administration Route - Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 529: Africa 16-Year Perspective for Antifungal Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Route of Administration, Topical Route of Administration and Parenteral Route of Administration for the Years 2014, 2025 & 2030

IV. COMPETITION